• Ivan Marković, Marina Božan, Tomislav Perković, Katarina Paušek, Vanja Nedeljković, Marina Perković, Tomislav Kelava, Marinko Artuković, and Stipić MarkovićAsjaASpecial Hospital for Pulmonary Diseases, Zagreb, Croatia..
• Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
• Medicine (Baltimore). 2022 Jul 29; 101 (30): e29571e29571.

AbstractConcerns have been raised about allergic reactions to messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines. A history of allergic reactions, including anaphylaxis to drugs, has been frequently reported in individuals with anaphylaxis to mRNA vaccines. To estimate the rate of immediate allergic reactions in patients with a history of drug allergy or other allergic disorders. We included adult patients who had received at least 1 dose of an mRNA COVID-19 vaccine at the Special Hospital for Pulmonary Diseases between March 1, 2021, and October 1, 2021, and who reported a history of drug allergy or other allergic diseases (asthma, allergic rhinitis, atopic dermatitis, food or insect venom allergy, mastocytosis, idiopathic anaphylaxis, acute or chronic urticaria, and/or angioedema). Immediate allergic reactions, including anaphylaxis, occurring within 4 hours of vaccination were recorded. Six immediate allergic reactions were noted in the cohort of 1679 patients (0.36%). One patient experienced anaphylaxis (0.06%), which resolved after epinephrine administration, and the other reactions were mild and easily treatable. Most patients with a history of allergies can safely receive an mRNA COVID-19 vaccine, providing adequate observation periods and preparedness to recognize and treat anaphylaxis.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

30 keywords...

hide…